252 related articles for article (PubMed ID: 21855298)
1. Triheptanoin--a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?
Borges K; Sonnewald U
Epilepsy Res; 2012 Jul; 100(3):239-44. PubMed ID: 21855298
[TBL] [Abstract][Full Text] [Related]
2. Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models.
Willis S; Stoll J; Sweetman L; Borges K
Neurobiol Dis; 2010 Dec; 40(3):565-72. PubMed ID: 20691264
[TBL] [Abstract][Full Text] [Related]
3. Triheptanoin in acute mouse seizure models.
Thomas NK; Willis S; Sweetman L; Borges K
Epilepsy Res; 2012 May; 99(3):312-7. PubMed ID: 22260920
[TBL] [Abstract][Full Text] [Related]
4. Modification of Astrocyte Metabolism as an Approach to the Treatment of Epilepsy: Triheptanoin and Acetyl-L-Carnitine.
Hadera MG; McDonald T; Smeland OB; Meisingset TW; Eloqayli H; Jaradat S; Borges K; Sonnewald U
Neurochem Res; 2016 Feb; 41(1-2):86-95. PubMed ID: 26433381
[TBL] [Abstract][Full Text] [Related]
5. Triheptanoin partially restores levels of tricarboxylic acid cycle intermediates in the mouse pilocarpine model of epilepsy.
Hadera MG; Smeland OB; McDonald TS; Tan KN; Sonnewald U; Borges K
J Neurochem; 2014 Apr; 129(1):107-19. PubMed ID: 24236946
[TBL] [Abstract][Full Text] [Related]
6. Triheptanoin reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy.
Kim TH; Borges K; Petrou S; Reid CA
Epilepsy Res; 2013 Jan; 103(1):101-5. PubMed ID: 23196212
[TBL] [Abstract][Full Text] [Related]
7. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
[TBL] [Abstract][Full Text] [Related]
8. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. II. Effects on lipolysis, glucose production, and liver acyl-CoA profile.
Gu L; Zhang GF; Kombu RS; Allen F; Kutz G; Brewer WU; Roe CR; Brunengraber H
Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E362-71. PubMed ID: 19903863
[TBL] [Abstract][Full Text] [Related]
9. Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin.
Schwarzkopf TM; Koch K; Klein J
Neuroscience; 2015 Aug; 300():201-9. PubMed ID: 25982559
[TBL] [Abstract][Full Text] [Related]
10. Alternative Fuels in Epilepsy and Amyotrophic Lateral Sclerosis.
Tefera TW; Tan KN; McDonald TS; Borges K
Neurochem Res; 2017 Jun; 42(6):1610-1620. PubMed ID: 27868154
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases.
Wehbe Z; Tucci S
J Inherit Metab Dis; 2020 May; 43(3):385-391. PubMed ID: 31778232
[TBL] [Abstract][Full Text] [Related]
12. Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency.
Karunanidhi A; Basu S; Zhao XJ; D'Annibale O; Van't Land C; Vockley J; Mohsen AW
Mol Genet Metab; 2023 Nov; 140(3):107689. PubMed ID: 37660571
[TBL] [Abstract][Full Text] [Related]
13. Triheptanoin protects against status epilepticus-induced hippocampal mitochondrial dysfunctions, oxidative stress and neuronal degeneration.
Tan KN; Simmons D; Carrasco-Pozo C; Borges K
J Neurochem; 2018 Feb; 144(4):431-442. PubMed ID: 29222946
[TBL] [Abstract][Full Text] [Related]
14. Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse.
Tucci S; Floegel U; Beermann F; Behringer S; Spiekerkoetter U
J Lipid Res; 2017 Jan; 58(1):196-207. PubMed ID: 27884962
[TBL] [Abstract][Full Text] [Related]
15. Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders.
Sklirou E; Alodaib AN; Dobrowolski SF; Mohsen AA; Vockley J
Front Genet; 2020; 11():598760. PubMed ID: 33584796
[TBL] [Abstract][Full Text] [Related]
16. Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis.
Tefera TW; Wong Y; Barkl-Luke ME; Ngo ST; Thomas NK; McDonald TS; Borges K
PLoS One; 2016; 11(8):e0161816. PubMed ID: 27564703
[TBL] [Abstract][Full Text] [Related]
17. Interrelations between C4 ketogenesis, C5 ketogenesis, and anaplerosis in the perfused rat liver.
Deng S; Zhang GF; Kasumov T; Roe CR; Brunengraber H
J Biol Chem; 2009 Oct; 284(41):27799-27807. PubMed ID: 19666922
[TBL] [Abstract][Full Text] [Related]
18. Tutorial: Triheptanoin and Nutrition Management for Treatment of Long-Chain Fatty Acid Oxidation Disorders.
Norris MK; Scott AI; Sullivan S; Chang IJ; Lam C; Sun A; Hahn S; Thies JM; Gunnarson M; McKean KN; Merritt JL
JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):230-238. PubMed ID: 33085788
[TBL] [Abstract][Full Text] [Related]
19. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats.
Kinman RP; Kasumov T; Jobbins KA; Thomas KR; Adams JE; Brunengraber LN; Kutz G; Brewer WU; Roe CR; Brunengraber H
Am J Physiol Endocrinol Metab; 2006 Oct; 291(4):E860-6. PubMed ID: 16705058
[TBL] [Abstract][Full Text] [Related]
20. Triheptanoin for the treatment of brain energy deficit: A 14-year experience.
Mochel F
J Neurosci Res; 2017 Nov; 95(11):2236-2243. PubMed ID: 28688166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
